FRANKLIN, Mass., April 23, 2012 /PRNewswire/ -- Arthrosurface, Inc. ( www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, announced that, in March, it surpassed $100 Million in cumulative net revenue. While this milestone is a significant financial achievement for the Company, its management believes that this milestone evidences the ever growing population of patients seeking alternatives to total joint replacement procedures. "Joint preservation, getting patients back to an active lifestyle and delaying conventional joint replacements has been our goal from the beginning," said Steve Ek, COO.
Arthrosurface contends it is the first and only company to develop a line of anatomic inlay implants for early joint disease and remains the leader in patient-matching metallic resurfacing. With more than 160 different implant sizes and shapes, the Arthrosurface joint platform could be considered the best first implant for early joint arthritis. Its resurfacing implants are thin, contoured, sized according to the defect and shaped to the patient's native joint surface. It is believed that there is no other orthopaedics company in the world with products that allow surgeons to intraoperatively and directly assess the joint status and choose a matching implant that, during the surgical procedure, serves the specific clinical need of the patient. With Arthrosurface's HemiCAP® resurfacing, the implant is matched to the patient. This implant-fitting concept is contrary to standard joint replacement where the patient is "fitted" to an implant through a series of large bone and soft tissue cuts.
Arthrosurface's President, Steve Tallarida, said, "We knew the idea of intervening sooner rather than later, when joint damage is limited, went against the conventional wisdom of traditional orthopaedics. In the world of total joints, treatment is typically delayed until significant joint destruction has occurred. We decided to take our cue from other disciplines, such as cardiology and dentistry, where stents and fillings are the first line choices for early intervention. Patients should have the option of considering an interim treatment in order to resume a normal lifestyle while hopefully delaying joint disease progression."SOURCE Arthrosurface, Inc.